Proven medication email designs you can use

This email aims to welcome new participants to the XALATAN Savings Card program and immediately guide them to use the card at the pharmacy to reduce out-of-pocket costs for their prescription. It also educates recipients on how to ensure they receive the brand-name medication as prescribed.

The email opens with a personalized greeting and immediately presents a high-impact savings offer, creating urgency and relevance by tying the benefit directly to the recipient’s prescription needs.

By including a visual mockup of the savings card with clear financial terms, like '$0 per 30-day fill', the email reduces cognitive load and builds trust through transparent, easy-to-digest value messaging.

Add a visual countdown timer or urgency indicator near the CTA to reinforce time-sensitive savings, especially since the offer is tied to pharmacy visits and prescription refills that may be delayed. • Include a small testimonial or patient quote near the education section to humanize the warning about generic substitution and increase perceived trust in the brand’s advocacy for patient care.

This email aims to inform healthcare professionals and stakeholders about the regulatory approval of finerenone in Japan for chronic heart failure patients with LVEF ≥40%, positioning Bayer as a leader in cardiovascular innovation and reinforcing confidence in the drug’s clinical value.

Bayer strategically anchors its message in clinical authority by citing the New England Journal of Medicine and ESC Congress 2024, lending credibility to finerenone’s approval and subtly positioning it as a gold-standard therapy in a crowded market.

The email effectively segments its audience by explaining heart failure subtypes (HFrEF, HFmrEF, HFpEF) with clear LVEF thresholds, ensuring medical professionals immediately recognize the drug’s precise therapeutic niche and relevance to their patient populations.

Add a visual timeline or infographic in the Education Section to illustrate finerenone’s global approval journey and Phase III trial milestones, helping readers quickly grasp the drug’s development trajectory and market expansion. • Include a short patient impact quote or statistic near the CTA to humanize the data, e.g., 'This approval could benefit over 1.2 million Japanese patients living with HF and LVEF ≥40%', to strengthen emotional resonance and urgency.

This email aims to inform healthcare professionals and stakeholders about the European Union’s approval of Lynkuet™ (elinzanetant) for treating moderate to severe vasomotor symptoms linked to menopause or endocrine therapy for breast cancer, while reinforcing Bayer’s leadership in women’s health innovation.

The email strategically anchors its message in patient impact by quoting clinical experts who emphasize how disruptive vasomotor symptoms are to daily life, making the approval feel personally relevant rather than purely regulatory.

By clearly segmenting scientific detail into labeled subsections like 'About elinzanetant' and 'Clinical Development Program,' the email respects the reader’s time while still delivering comprehensive data that builds credibility without overwhelming.

Add a visual timeline or infographic summarizing the OASIS Phase III trial structure to help readers quickly grasp the scale and rigor of clinical evidence without wading through dense paragraphs. • Include a direct CTA button labeled 'Download Full Prescribing Information' or 'Request Sample' near the top of the email to convert informed interest into actionable next steps for HCPs.

To inform the public and stakeholders that Novo Nordisk is taking legal action against Hims & Hers for marketing unsafe, unapproved versions of Wegovy® and Ozempic®, emphasizing patient safety and the company’s commitment to protecting FDA-approved treatments.

Novo Nordisk strategically frames its legal action not as a corporate dispute but as a moral defense of patient safety, directly linking Hims & Hers’ practices to life-threatening risks like immune responses and overdoses to evoke urgency and public sympathy.

By citing authoritative voices like the FDA, AMA, and Endocrine Society, the email leverages third-party credibility to reinforce its claims, transforming a legal notice into a public health warning that resonates with both consumers and medical professionals.

Add a visual element such as a warning icon or red banner near the headline to immediately signal urgency and danger, helping readers grasp the critical nature of the message before diving into text-heavy paragraphs. • Include a short, bolded summary box at the top that distills the legal action, key risks, and patient safety message into 3 bullet points, improving scannability for time-constrained readers and reinforcing the core message.

This email aims to inform stakeholders, investors, and the public about Monsanto’s proposed class settlement agreement regarding Roundup™ litigation, while reinforcing Bayer’s strategic commitment to resolving legal uncertainties and maintaining regulatory clarity for agricultural innovation.

The email strategically frames the settlement not as an admission of guilt but as a proactive financial and legal containment measure, which preserves brand credibility while addressing stakeholder concerns with transparency and long-term planning.

By explicitly separating the class settlement from the Supreme Court case and explaining how each reinforces the other, the message builds a narrative of strategic coherence, helping audiences understand the company’s layered approach to risk mitigation and regulatory alignment.

Add a visual timeline or infographic in the Education Section to illustrate the progression of litigation, settlement structure, and financial impact, this would improve comprehension for non-legal audiences and reinforce the long-term nature of the funding commitment. • Place the 'Bayer Investor and Media Update' CTA higher in the email, ideally after the headline and summary paragraph, to prioritize immediate engagement from target stakeholders before they scroll into dense legal details.

This email aims to inform medical professionals and stakeholders about the positive Phase III clinical trial results of Bayer’s investigational drug asundexian for secondary stroke prevention, while reinforcing Bayer’s scientific leadership in cardiovascular medicine.

The email leads with a bold, data-driven headline that immediately communicates clinical impact, a 26% reduction in stroke, which grabs attention and establishes credibility before the reader even scrolls further.

It strategically embeds expert quotes from principal investigators and global R&D leaders to humanize the data, lending authority and emotional resonance to the scientific findings without sacrificing precision or professionalism.

Add a visual summary graphic or infographic near the top to illustrate the 26% stroke reduction and safety profile, helping time-constrained readers grasp key outcomes at a glance without wading through dense text. • Include a direct CTA button labeled 'Download Full Study Results' or 'Request Investigator Materials' above the fold to convert interest into action, rather than relying solely on a passive text link buried in the footer.

This email aims to inform healthcare professionals and stakeholders about the European Union’s approval of Eylea™ 8 mg for a third retinal indication, specifically for macular edema following retinal vein occlusion, while reinforcing Bayer’s leadership in ophthalmology innovation and clinical efficacy.

The email strategically anchors its message in clinical trial data, specifically the QUASAR study, to build credibility and demonstrate real-world patient benefits, such as extended dosing intervals and maintained visual acuity, which directly address treatment burden concerns.

By including direct quotes from both a leading ophthalmologist and a Bayer executive, the email blends scientific authority with corporate vision, creating a dual-layered persuasive appeal that resonates with both clinical and strategic decision-makers.

Add a visual timeline or infographic summarizing the QUASAR trial results, especially the 60% of patients achieving 4+ month dosing intervals, to make complex data more digestible and emotionally resonant for time-constrained clinicians. • Include a clear, visually distinct CTA button (e.g., 'Download Full Trial Data') near the top of the email to reduce friction for readers seeking deeper clinical evidence, rather than relying solely on a text-based link buried in the footer.

This email aims to express sincere gratitude to customers for their support throughout 2025 while subtly reinforcing brand values and loyalty by highlighting milestones, social impact, and product achievements. It also seeks to drive last-minute sales by appending a time-sensitive discount at the end.

The email masterfully blends emotional storytelling with tangible business milestones, making the brand feel human and trustworthy while still showcasing growth and impact without sounding boastful.

By anchoring the message in gratitude and tying it to real customer feedback and social responsibility, the brand deepens emotional connection and subtly reinforces why customers should continue supporting them beyond just product utility.

Add a visual timeline or icon-based summary of the 2025 milestones to break up dense text and improve scannability, helping readers quickly grasp key achievements without reading every line. • Reposition the CTA higher in the email, perhaps after the first milestone section, with a secondary reminder at the bottom, to capture attention earlier while maintaining the emotional flow.

This email aims to encourage caregivers of patients with rare seizure disorders to participate in a survey about harmful or disruptive behaviors, helping to gather insights that can improve support systems and communication with healthcare providers. It leverages social proof by highlighting that over 500 caregivers have already contributed.

The email powerfully opens with social proof, highlighting that over 500 caregivers have already shared their stories, to build trust and reduce hesitation, making recipients feel part of a meaningful, collective effort rather than isolated in their experience.

It strategically uses concise, emotionally resonant statistics, like 53% witnessing physical aggression, to quickly validate the caregiver’s reality and underscore the urgency of participation, turning abstract concerns into tangible, relatable data that compels action.

Add a brief testimonial quote from a previous participant to humanize the impact, e.g., 'My answers helped my child’s doctor adjust her care plan', to strengthen emotional resonance and reduce perceived effort in completing the survey. • Include a progress indicator or estimated time to complete (e.g., 'Takes 5 minutes') near the CTA to lower psychological barriers and increase conversion by managing expectations around time investment.

To publicly denounce Hims & Hers for illegally compounding and misleadingly marketing unapproved semaglutide products, while reinforcing Novo Nordisk’s commitment to patient safety and FDA-approved standards.

Novo Nordisk strategically frames its response as a patient safety imperative, not just a corporate dispute, which builds public trust by positioning the brand as a guardian of regulatory integrity and medical ethics.

By explicitly contrasting its FDA-approved Wegovy® with untested compounded alternatives, the email leverages regulatory authority as a persuasive differentiator, subtly guiding consumers toward the legitimate, vetted product.

Add a visual comparison table or side-by-side graphic showing FDA-approved vs. compounded semaglutide to make the safety and regulatory differences instantly digestible for non-medical readers. • Include a short patient testimonial or quote from a healthcare provider affirming the importance of FDA-approved GLP-1 medications to humanize the message and strengthen emotional resonance.